Umbilical cord blood and peripheral blood-derived regulatory T cells therapy: Progress in type 1 diabetes

Yuanjie Bi; Ran Kong; Yani Peng; Haibo Yu; Zhiguang Zhou

doi:10.1016/j.clim.2023.109716

Umbilical cord blood and peripheral blood-derived regulatory T cells therapy: Progress in type 1 diabetes

Clin Immunol. 2023 Oct:255:109716. doi: 10.1016/j.clim.2023.109716. Epub 2023 Aug 5.

Authors

Yuanjie Bi¹, Ran Kong¹, Yani Peng¹, Haibo Yu², Zhiguang Zhou³

Affiliations

¹ National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Hunan Engineering Research Center of Cell Therapy for Diabetes, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China.
² National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Hunan Engineering Research Center of Cell Therapy for Diabetes, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China. Electronic address: yuhaibo616@csu.edu.cn.
³ National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Hunan Engineering Research Center of Cell Therapy for Diabetes, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China. Electronic address: zhouzhiguang@csu.edu.cn.

PMID: 37544491
DOI: 10.1016/j.clim.2023.109716

Abstract

Regulatory T cells (Tregs) are key regulators for the inflammatory response and play a role in maintaining the immune tolerance. Type 1 diabetes (T1D) is a relatively common autoimmune disease that results from the loss of immune tolerance to β-cell-associated antigens. Preclinical models have demonstrated the safety and efficacy of Tregs given in transplant rejection and autoimmune diseases such as T1D. Adoptive transfer of Tregs has been utilized in clinical trials for over a decade. However, the achievement of the adoptive transfer of Tregs therapy in clinical application remains challenging. In this review, we highlight the characterization of Tregs and compare the differences between umbilical cord blood and adult peripheral blood-derived Tregs. Additionally, we summarize conditional modifications in the expansion of Tregs in clinical trials, especially for the treatment of T1D. Finally, we discuss the existing technical challenges for Tregs in clinical trials for the treatment of T1D.

Keywords: Adoptive cell therapy; Peripheral blood; Regulatory T cells; Type 1 diabetes; Umbilical cord blood.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Autoimmune Diseases*
Diabetes Mellitus, Type 1* / therapy
Fetal Blood
Humans
Immune Tolerance
T-Lymphocytes, Regulatory